INS and inflammatory bowel disease: currently, pparγ ligands are used in clinics for their anti-inflammatory and insulin-sensitizing effects in diseases such as psoriasis, atherosclerosis, inflammatory bowel disease and type 2 diabetes [13], [14], [70]–[74].